Skip to the page

Data / Drug companies / Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc.: 65 products in the FDA NDC directory, labeler code 50419

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Bayer HealthCare Pharmaceuticals Inc. (labeler code 50419) lists 65 products in the FDA National Drug Code Directory, covering 24 finished drugs by generic name. By type: 64 prescription drugs, 1 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on June 12, 2026.

The request: Watch Bayer HealthCare Pharmaceuticals Inc. (FDA labeler code 50419): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
50419
Products in commercial distribution
65
Packages
152
Finished drugs by generic name
24
Prescription products
64
Over the counter products
0
Flagged as original packager
57 of 57 products that carry the flag
Started marketing in the last 12 months
12
Earliest marketing start
October 22, 1987
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)6396.9%
Drugs for further processing11.5%
Biologics (BLA)11.5%

Products by type

TypeProductsShare
Prescription drugs6498.5%
Drugs for further processing11.5%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Gadoquatrane111
Estradiol753
Riociguat52
Iopromide41
Larotrectinib42
Gadobutrol36
Finerenone31
Levonorgestrel331
Drospirenone and ethinyl estradiol216
Drospirenone and estradiol21
Sorafenib28
Ciprofloxacin241
Nifurtimox21
Ciprofloxacin hydrochloride236
Darolutamide11
Interferon beta-1b11
Gadoxetate disodium11
Estradiol and levonorgestrel11
Praziquantel12
Estradiol valerate and estradiol valerate/dienogest12
Elinzanetant11
Radium ra 223 dichloride11
Sevabertinib11
Regorafenib11

Dosage forms

Dosage formProductsShare
Injection1929.2%
Tablet, film coated1929.2%
Kit812.3%
Patch812.3%
Capsule34.6%
Intrauterine device34.6%
Tablet23.1%
Solution, concentrate23.1%
Injection, solution11.5%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Ambelvist50419-332InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-331InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-330InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-329InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-328InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-327InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-326InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-324InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-323InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-322InjectionNew drug applications (NDA)June 12, 2026
Ambelvist50419-321InjectionNew drug applications (NDA)June 12, 2026
Hyrnuo50419-397Tablet, film coatedNew drug applications (NDA)November 19, 2025
Lynkuet50419-475CapsuleNew drug applications (NDA)October 24, 2025
Finerenone50419-542TabletDrugs for further processingJuly 13, 2025
Nexavar50419-489Tablet, film coatedNew drug applications (NDA)October 2, 2023
Vitrakvi50419-393Solution, concentrateNew drug applications (NDA)December 6, 2022
Ultravist50419-348InjectionNew drug applications (NDA)June 8, 2022
Ultravist50419-347InjectionNew drug applications (NDA)June 8, 2022
Kerendia50419-542TabletNew drug applications (NDA)July 9, 2021
Kerendia50419-541Tablet, film coatedNew drug applications (NDA)July 9, 2021
Kerendia50419-540Tablet, film coatedNew drug applications (NDA)July 9, 2021
Lampit50419-751Tablet, film coatedNew drug applications (NDA)October 1, 2020
Lampit50419-750Tablet, film coatedNew drug applications (NDA)October 1, 2020
Nubeqa50419-395Tablet, film coatedNew drug applications (NDA)July 31, 2019
Vitrakvi50419-392Solution, concentrateNew drug applications (NDA)July 26, 2019

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.